Edwards Lifesciences posted a Q2 profit and revenue beat, supported by strong demand for its artificial heart valves for complex cardiac procedures. Shares rose nearly 7% in extended trading on the upside versus analysts’ estimates.
Edwards Lifesciences posted a Q2 profit and revenue beat, supported by strong demand for its artificial heart valves for complex cardiac procedures. Shares rose nearly 7% in extended trading on the upside versus analysts’ estimates.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
